H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on JSPR stock, giving a Buy rating today.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Emily Bodnar’s rating is based on the promising results from Jasper Therapeutics’ SPOTLIGHT trial, which demonstrated a clear dose response in patients treated with the 180 mg dose of briquilimab for chronic inducible urticaria. The trial results showed significant improvements in serum tryptase levels, a key biomarker, with 83% of patients in the 180 mg cohort experiencing a decline below the lower limit of quantification. This indicates a strong efficacy profile for the higher dose compared to lower doses.
Additionally, the safety profile of the 180 mg dose was favorable, with no serious adverse events or treatment discontinuations reported. The clinical response rates were impressive, with a complete response in 92% of patients and a 100% clinical response rate, suggesting that the 180 mg dose provides a more durable response. These factors contribute to the confidence in the upcoming BEACON trial results and support the Buy rating for Jasper Therapeutics’ stock.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Agenus, and Femasys. According to TipRanks, Bodnar has an average return of -6.6% and a 29.23% success rate on recommended stocks.